Orthofix 8-K: Executive Changes, Compensation & Disclosure

TL;DR

**Orthofix filed an 8-K on Jan 17, signaling executive changes and compensation updates from Jan 15.**

AI Summary

Orthofix Medical Inc. filed an 8-K on January 17, 2024, reporting an event that occurred on January 15, 2024. This filing indicates a change in executive leadership or compensatory arrangements, as per Item 5.02, and also includes Regulation FD Disclosure and Financial Statements and Exhibits. This matters to investors because changes in leadership or executive compensation can signal shifts in company strategy, financial health, or governance, potentially impacting future stock performance.

Why It Matters

Changes in executive leadership or compensation can significantly influence a company's strategic direction and operational stability, directly affecting investor confidence and stock valuation.

Risk Assessment

Risk Level: medium — Changes in executive leadership can introduce uncertainty regarding future company performance and strategic direction, posing a moderate risk to investors.

Analyst Insight

Investors should monitor subsequent filings or company announcements for specific details regarding the executive changes and compensatory arrangements, as these will clarify the potential impact on Orthofix's future operations and strategy.

Key Numbers

• $0.10 — par value per share (common stock par value for Orthofix Medical Inc.)

Key Players & Entities

• Orthofix Medical Inc. (company) — the registrant filing the 8-K
• January 15, 2024 (date) — date of the earliest event reported in the 8-K
• January 17, 2024 (date) — date the 8-K was filed
• $0.10 (dollar_amount) — par value per share of common stock
• OFIX (company) — trading symbol for Orthofix Medical Inc.

Forward-Looking Statements

• Orthofix Medical Inc. will provide more detailed information about the executive changes and compensatory arrangements in an upcoming filing or press release. (Orthofix Medical Inc.) — medium confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.10 — nge on which registered Common stock, $0.10 par value per share OFIX Nasdaq Glo
• $12,500 — ng such date of termination), and (iii) $12,500 to be used for outplacement services. I

Filing Documents

• ofix-20240115.htm (8-K) — 49KB
• ofix-ex10_1.htm (EX-10.1) — 147KB
• ofix-ex99_1.htm (EX-99.1) — 19KB
• img236010591_0.jpg (GRAPHIC) — 6KB
• 0000950170-24-005068.txt ( ) — 363KB
• ofix-20240115.xsd (EX-101.SCH) — 23KB
• ofix-20240115_htm.xml (XML) — 4KB

02 Departure of Directors of Principal Officers; Election of Directors; Appointment of Principal Officers

Item 5.02 Departure of Directors of Principal Officers; Election of Directors; Appointment of Principal Officers. On January 15, 2024, Julie Andrews began service as Chief Financial Officer of Orthofix Medical Inc. (the “Company”). As an inducement to entering into employment with the Company, Ms. Andrews was granted, as of January 15, 2024, (i) performance-based vesting restricted stock units that settle 65,934 shares of common stock at target achievement, (ii) time-based vesting restricted stock units that settle into 32,967 shares of common stock, and (iii) stock options to purchase 76,878 shares of common stock. The performance-based vesting restricted stock units vest at the end of a 3-year performance period based on the Company’s total stockholder return relative to an industry peer group index during such period, while the time-based vesting restricted stock units vest in equal tranches over three years. The stock options vest upon achievement of both service- and performance-based criteria, whichever is the later of (a) the date certain service-based conditions are met (which will be met over three years) and (b) the date that the average closing price of the Company’s common stock over a one-month calendar period has been equal to or great than 150% of the closing price of the Company’s common stock on the grant date. The awards were granted pursuant to a standalone inducement plan, the Orthofix Medical Inc. 2024 CFO Inducement Plan (the “2024 CFO Inducement Plan”), which plan was approved by the Board as of January 15, 2024. A copy of the 2024 CFO Inducement Plan has been filed as Exhibit 4.2 , and copies of the forms of award agreements have been filed as Exhibits 4.3 , 4.4 and 4.5 , respectively, to the Company’s Registration Statement on Form S-8 (Registration No. 333-276506) filed with the Securities and Exchange Commission on January 12, 2024. The foregoing descriptions of the 2024 CFO Induc

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 16, 2024, the Company issued a press release regarding Ms. Andrews beginning service as the Company’s Chief Financial Officer and certain of the other matters described in Item 5.02. The information furnished in this Item 7.01, including the exhibit furnished herewith as Exhibit 99.1, will not be treated as “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section. This information will not be deemed incorporated by reference into any filing under the Securities Act, or into another filing under the Exchange Act, unless that filing expressly incorporates by reference this Item 7.01 of this report.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits 10.1 Change in Control and Severance Agreement, dated as of January 15, 2024, between Orthofix Medical Inc. and Julie Andrews. 99.1 Press release, dated January 16, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Orthofix Medical Inc. By: /s/ Kimberley Elting Kimberley Elting Interim Chief Legal Officer Date: January 17, 2024

View Full Filing

View this 8-K filing on SEC EDGAR